Citi Raises Price Target on Lexicon Pharmaceuticals to $3.10
On May 11, 2026, Citi raised its price target for Lexicon Pharmaceuticals (NASDAQ:LXRX) from $2.30 to $3.10 and maintained a Buy rating following the company's Q1 earnings report. The firm reported better-than-expected revenue of $21.1M driven by a milestone payment from Novo Nordisk.
Topics: biopharmaceutical earnings_beat price_target_increase